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ARTICLE
Retinol saturase coordinates liver metabolism by
regulating ChREBP activity
Steffi Heidenreich1, Nicole Witte1, Pamela Weber1, Isabel Goehring1, Alexander Tolkachov1,
Christian von Loeffelholz2,3,4, Stephanie Döcke2, Michael Bauer3,4, Martin Stockmann5, Andreas F. H. Pfeiffer2,6,
Andreas L. Birkenfeld 7,8, Matthias Pietzke9, Stefan Kempa9, Matthias Muenzner1 & Michael Schupp 1
The liver integrates multiple metabolic pathways to warrant systemic energy homeostasis.
An excessive lipogenic flux due to chronic dietary stimulation contributes to the development
of hepatic steatosis, dyslipidemia and hyperglycemia. Here we show that the oxidoreductase
retinol saturase (RetSat) is involved in the development of fatty liver. Hepatic RetSat
expression correlates with steatosis and serum triglycerides (TGs) in humans. Liver-specific
depletion of RetSat in dietary obese mice lowers hepatic and circulating TGs and normalizes
hyperglycemia. Mechanistically, RetSat depletion reduces the activity of carbohydrate
response element binding protein (ChREBP), a cellular hexose-phosphate sensor and inducer
of lipogenesis. Defects upon RetSat depletion are rescued by ectopic expression of ChREBP
but not by its putative enzymatic product 13,14-dihydroretinol, suggesting that RetSat affects
hepatic glucose sensing independent of retinol conversion. Thus, RetSat is a critical regulator
of liver metabolism functioning upstream of ChREBP. Pharmacological inhibition of liver
RetSat may represent a therapeutic approach for steatosis.
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Retinol saturase (RetSat) is an NADH/NADPH- or FADH-dependent oxidoreductase and strongly expressed in liver,adipose tissue and kidney1. Major transcriptional reg-
ulators of RetSat expression include peroxisome proliferator-
activated receptor α (PPARα) and forkhead box O1 (FoxO1) in
liver2–4, and PPARγ in adipose tissue, where RetSat’s expression
is robustly induced during the differentiation of precursor cells
into adipocytes5. Cellular RetSat protein localizes primarily to the
endoplasmic reticulum and catalyzes the conversion of retinol to
13,14-dihydroretinol (13,14-dhretinol)1, 5, 6, a retinoid metabolite
that can act as precursor for the generation of 13,14-dihydror-
etinoic acid7. Although it was found that these dihydroretinoids
bind retinoic acid receptors (RAR) with lower affinities than their
non-reduced forms8, their biological relevance is largely
unknown. A recent study identified the 9-cis-isomer of 13,14-
dihydroretinoic acid as an endogenous ligand for retinoid X
receptor (RXR)9. Whether RetSat is a biologically relevant
enzyme for providing precursors for endogenous RXR ligand
generation is currently unknown.
We previously reported that RetSat depletion in adipocyte
precursor cells impaired their adipogenic conversion in vitro and
found its expression in adipose tissue downregulated in obesity5.
Surprisingly, reduced adipogenesis upon RetSat depletion was not
overcome by providing 1314-dhretinol, suggesting that 13,14-
dhretinol generation is not responsible for its pro-adipogenic
function. On the other hand, complete inactivation of RetSat’s
enzymatic activity by mutating the dinucleotide-binding motif
blunted its effects, indicating that RetSat promotes adipogenesis
via an additional, yet unknown enzymatic reaction5.
Besides promoting adipogenesis and conferring cellular sensi-
tivity towards oxidative stress10, deeper insights into RetSat’s
biological functions are missing. Mice with whole-body germline
deletion of RetSat exhibit altered body composition with an
unexpected shift to higher fat mass but, so far, have not been
associated with any other phenotype11. A bioinformatic analysis
of gene expression profiles from type 2 diabetes-related animal
models and human tissue samples identified RetSat as the gene
with the highest differential mRNA expression across all analyzed
data sets12, suggesting a much broader involvement of RetSat in
regulating glucose and fatty acid metabolism.
To identify novel functions of RetSat we studied the liver, the
tissue with the strongest RetSat expression1, 5. We found that
RetSat expression correlates with liver steatosis in humans and
that its hepatic depletion lowers liver triglycerides (TGs) and
improves metabolic parameters in dietary obese mice, at least in
part, by interfering with the activity of the cellular hexose-
phosphate sensor carbohydrate response element-binding protein
(ChREBP)13. These findings link RetSat to sugar sensing in
hepatocytes and may allow for novel therapeutic approaches for
metabolic liver diseases.
Results
RetSat regulates glycolytic and lipogenic pathways in hepato-
cytes. We found RetSat protein robustly expressed in several
metabolically relevant organs and highest in liver, followed by
kidney, epididymal white adipose tissue and muscle (Fig. 1a,
whole blot shown in Supplementary Fig. 9), correlating well with
its known mRNA expression pattern1, 5. To gain functional
insights, we performed gene expression profiling of primary
mouse hepatocytes that were depleted of RetSat by siRNA for
48 h (Fig. 1b, whole blot shown in Supplementary Fig. 10).
Unexpectedly, RetSat depletion in hepatocytes resulted in a rather
high number of 1602 regulated genes (P< 0.05 (two tailed Stu-
dents’s t-test) and fold-change ≥ 1.25 cutoff), suggesting that
RetSat’s enzymatic function may couple to the control of gene
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Fig. 1 RetSat controls glycolytic and lipogenic pathways in primary
hepatocytes. a RetSat protein expression in metabolically relevant mouse
tissues was analyzed by immunoblotting. b RetSat protein expression, 48 h
after transfecting Control or RetSat siRNA, was determined by
immunoblotting. c Top five enriched pathways of genes that are regulated
by RetSat depletion in hepatocytes were identified by DAVID functional
annotation of Affymetrix gene expression profiles. d mRNA expression of
selected genes in siControl or siRetSat hepatocytes was determined by
qPCR. Data are shown as mean± s.d., n= 6 independent transfections of
hepatocyte cultures from two mice; *P< 0.05 by two-tailed t-test. An
independent experiments yielded similar results. e Hepatocytes depleted of
RetSat were incubated with 13C-glucose for 5 min and 13C-pyruvate
labelling analyzed by mass spectroscopy. Data are shown as mean± s.d.,
n= 4 independent transfections of hepatocyte cultures from the same
mouse; *P< 0.05 by two-tailed t-test. An independent experiment yielded
similar results. f Incorporation of 14C-acetate into extractable lipids was
assessed in hepatocytes treated as indicated. Data are shown as
mean± s.d., n= 6 independent transfections of hepatocyte cultures from
the same mouse; significance between siControl and siRetSat was tested by
two-tailed t-test and *P< 0.05. An independent experiment yielded similar
results. g Palmitate/palmitoleate ratio in siControl- or siRetSat-treated
hepatocytes was assessed by mass spectroscopy. Data are shown as
mean± s.d., n= 4 independent transfections of hepatocyte cultures from
the same mouse; *P< 0.05 by two-tailed t-test. An independent
experiment yielded similar results
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expression. Regulated genes enriched primarily to gene ontology
(GO) pathways of intermediary cell metabolism of oxoacids,
hexoses/monosaccharides, and amino acids (top five terms shown
in Fig. 1c). Among genes related to hexose/monosaccharide
metabolism, we noticed that several glycolytic genes, including
aldolase (Aldoa), phosphofructokinase, liver (Pfkl) and pyruvate
kinase, liver (Pklr) were downregulated upon RetSat depletion
(Supplementary Fig. 1a). We validated the regulation of some of
these genes by quantitative PCR (qPCR) and extended our ana-
lysis to pathways downstream of glycolysis, namely de novo
lipogenesis and the elongation, esterification and desaturation of
fatty acids. Strikingly, many of these genes were also down-
regulated (Fig. 1d). We then tested whether altered gene
expression bears functional relevance and found a reduction in
glycolytic flux, de novo lipogenesis, and a lower palmitoleate/
palmitate ratio that indicates reduced palmitate desaturation in
RetSat-depleted hepatocytes (Figs. 1e-g). Thus, RetSat depletion
impairs glycolytic flux and lipid metabolism in primary
hepatocytes.
RetSat is elevated in obese mouse liver and controls lipid
metabolism. Given this functional relevance, we compared RetSat
mRNA levels in livers of lean and diet-induced, obese mice (body
weights of 29.7± 1.61 g vs. 47.9± 2.83 g, respectively) and found
it increased in obese animals (Fig. 2a). We next addressed whe-
ther RetSat regulates lipid metabolism in vivo. To acutely deplete
RetSat in livers of adult mice, we generated adenoviruses that
target βGal (Control) or RetSat by expressing shRNA. Tail-vein
injection of adenoviruses yields transient and highly liver-specific
expression, as validated by a FLAG-tagged protein that was
delivered similarly and detected only in liver (Supplementary
Fig. 1b). Depleting hepatic RetSat expression (Fig. 2b, whole blot
shown in Supplementary Fig. 11) in adult, NC-fed mice did not
change any of the metabolic parameters measured, when analyzed
6 days after virus injection (Supplementary Table 1). In contrast,
acute RetSat depletion in mice that were challenged by HS/HFD-
feeding before injecting viruses strongly reduced the liver TG
content (Fig. 2c, d). Consistently, hepatic expression of genes
involved in de novo lipogenesis and fatty acid elongation and
desaturation, including the enzyme that produces mono-
unsaturated fatty acids (MUFAs), stearoyl-CoA desaturase 1
(Scd1)14, was lower (Fig. 2e), resembling the consequences of
RetSat depletion in primary hepatocytes. Consistent with reduced
expression of genes like ATP citrate lyase (Acly), acetyl-CoA
carboxylase 1 (Acc1) and fatty acid synthase (Fasn) in shRetSat-
treated mice, liver de novo palmitate synthesis tended to be lower
(Fig. 2f). Food intake of HS/HFD-fed mice with hepatic RetSat
depletion was lower without reaching significance (Fig. 2g).
Serum levels of TG, non-esterified fatty acids (NEFAs) and blood
glucose were strongly reduced in both ad libitum-fed and fasted
mice (Fig. 2h-j). Lower blood glucose was not due to increased
insulin, since serum insulin was reduced (Fig. 2k). Glucose tol-
erance was enhanced in mice with liver-specific depletion of
RetSat, whereas the glucose-lowering effects of insulin were
comparable (Supplementary Fig. 2a, b, respectively). Basal Akt
phosphorylation (S473) was slightly higher in shRetSat-treated
mice and similar to control mice after the injection of insulin
(Supplementary Fig. 2c). Taken together, we found that RetSat
expression is elevated in livers of obese mice, and that its acute
depleting has profound metabolic effects in HS/HFD-fed, but not
in NC-fed mice.
Hepatic RETSAT correlates with obesity and steatosis in
humans. We then addressed whether RETSAT could be linked to
hepatic lipid metabolism in humans. In a set of liver samples
derived from abdominal surgery, RETSAT mRNA expression
correlated positively with patient body mass index (Fig. 3a).
Moreover, RETSAT expression showed a strong correlation with
the degree of steatosis (Fig. 3b), an established clinical parameter
determined by histology15, and the homeostatic model assess-
ment - insulin resistance index (HOMA-IR)16 (Fig. 3c). We also
identified correlations between RETSAT expression and serum
TG (Fig. 3d), and the percentage of MUFAs from total FA
(Fig. 3e). Thus, the pattern of RETSAT expression in liver samples
could imply a function in hepatic glucose and lipid metabolism in
humans.
RetSat regulates ChREBP and its target gene expression. We
next analyzed livers of HS/HFD-fed mice with or without RetSat
depletion in more detail to identify the underlying mechanisms of
reduced liver and serum TGs. Increased hepatic de novo lipo-
genesis contributes to both liver steatosis and elevated serum TG
upon HS/HFD-feeding17, 18. We therefore tested whether major
transcriptional regulators of de novo lipogenesis, sterol regulatory
element binding protein 1c (Srebp1c)19, liver x receptor alpha
(Nr1h3 = Lxrα)20, or ChREBP21–23 were affected by RetSat
depletion. Only ChREBP mRNA expression was decreased, with a
more pronounced reduction for the weakly expressed, but more
active β-isoform24–26 (Fig. 4a).
By analyzing liver protein expression we found that ChREBPα
(migrating at ~100 kDa) was strongly reduced, even more than its
mRNA regulation would predict (Fig. 4b, whole blot shown in
Supplementary Fig. 12). Protein of the β-isoform (migrating at
~75 kDa)25 was undetectable under either condition (Fig. 4b). In
accordance with lower levels of ChREBP protein, most of the
analyzed canonical target genes of ChREBP27–29 were reduced in
livers depleted of RetSat (Fig. 4c). Moreover, the ChREBP target
genes PKLR13 and acetyl-CoA carboxylase 1 (ACC1)30, 31 strongly
correlated with RETSAT expression in human liver samples
(Fig. 4d). Taken together, our data suggest a functional link
between RetSat and ChREBP. Thus, RetSat depletion may cause
at least some of the observed metabolic alterations by interfering
with hepatic ChREBP in HS/HFD-fed mice.
Although NC-fed mice depleted of hepatic RetSat lacked
obvious metabolic alterations, we asked whether ChREBP-
dependent responses were affected. Maximizing hepatic ChREBP
activity by 4 h re-feeding strongly induced the canonical target
genes Fasn30, 31 and regulator of G-protein signaling 16 (Rgs16)32
in livers of control mice. This induction was significantly
impaired in mice with hepatic RetSat depletion (Supplementary
Fig. 3a), indicating that hepatic RetSat depletion impairs ChREBP
activation also in mice fed NC. Since blood glucose levels during
re-feeding were similar in both groups (Supplementary Fig. 3b),
reduced ChREBP target gene expression is a primary effect of
depleting RetSat and not secondary due to lower blood glucose
levels. However, strongly reduced ChREBP protein levels and
impaired target gene expression in livers of HS/HFD-fed mice
may be due to both, direct effects of RetSat depletion and lower
blood glucose levels.
RetSat controls ChREBP activity and glucose sensing in
hepatocytes. ChREBP is a pivotal regulator of glycolysis and de
novo lipogenesis21. Our finding that RetSat depletion interferes
with ChREBP-dependent pathways is compatible with RetSat’s
function in primary hepatocytes (Fig. 1). In contrast to liver,
RetSat depletion in hepatocytes for 48 h did not affect mRNA or
protein levels of ChREBP (Fig. 5a). However, we found an overall
downregulation of canonical target genes of ChREBP27, 28
(Fig. 5b) but not of Lxrα (Supplementary Fig. 4), irrespective of
the siRNA target sequences used to deplete RetSat (Fig. 5c). Since
ChREBP protein levels were not changed, we asked whether
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-00430-w ARTICLE
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RetSat depletion reduces ChREBP activity. Indeed, a carbohydrate
response element (ChoRE)-driven luciferase reporter33, showing
the expected induction by high glucose, was less active in RetSat-
depleted hepatocytes (Fig. 5d). Moreover, ChREBP target genes
matched this activity pattern in primary hepatocytes when
exposed to either low or high glucose concentrations (Fig. 5e).
RetSat depletion impairs the nuclear accumulation of
ChREBP. Upon exposure to high glucose concentrations, cyto-
solic ChREBP translocates and accumulates in the nucleus34.
After validating the ChREBP antibody for immunofluorescence
(adenoviral ChREBP over-expression strongly induced ChREBP
staining, Supplementary Fig. 5a), we compared the nuclear signal
intensities of endogenous ChREBP in primary hepatocytes
exposed to low or high glucose concentrations. Insulin was added
to maximize ChREBP nuclear translocation35. We found that
high glucose conditions caused a moderate increase in nuclear
ChREBP staining (Fig. 6a). In hepatocytes depleted of RetSat
(Supplementary Fig. 5b), nuclear accumulation of ChREBP upon
high glucose was blunted (Fig. 6a, arrows, and quantification in
Fig. 6b). We then asked whether the putative enzymatic product
13,14-dhretinol can compensate for impaired ChREBP responses
due to RetSat depletion. Surprisingly, neither the reduced
induction of ChREBP target genes (Fig. 6c) nor lower de novo
lipogenesis (Fig. 6d) were rescued by providing 13,14-dhretinol,
suggesting that dhretinol formation is not the enzymatic reaction
required for ChREBP’s activity. We next asked whether a lack of
glucose metabolites could be responsible for reduced ChREBP
activity and found that RetSat-depleted cells contained higher
levels of certain glycolytic and pentose phosphate pathway
metabolites, including glucose 6-phosphate and sedoheptulose 7-
phosphate (Supplementary Fig. 6). This argues against a primary
defect in the generation of ChREBP-activating glucose metabo-
lites in RetSat-depleted hepatocytes. Interestingly, increased
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concentrations of glucose 6-phosphate were detected also in
ChREBP-depleted36 or ChREBP-deleted livers37, most likely due
to altered/impaired glucose-6-phosphate turnover. On the other
hand, adenoviral over-expression of ChREBP led to a partial
recovery of ChREBP target genes that were downregulated by
RetSat depletion (Fig. 6e, f). Notably, some of the genes down-
regulated by RetSat depletion, including glucokinase (Gck), were
not rescued by ectopic ChREBP (Gck mRNA reduced to 51.73±
15.79% in siRetSat versus siControl, and similarly reduced to
45.12± 20.51% in siRetSat + Adeno-ChREBP versus siControl
hepatocytes), suggesting that there are additional mechanisms by
which RetSat depletion interferes with gene expression.
We finally compared BioGPS profiles38, 39 of RetSat and
ChREBP and found a strikingly similar mRNA expression pattern
in different murine organs and cell types (Supplementary Fig. 7).
To evaluate whether RetSat links functionally to ChREBP in other
cell types, we depleted RetSat in mature 3T3-L140 adipocytes that,
like hepatocytes, robustly express both proteins (Supplementary
Fig. 8a). Indeed, the high-glucose induced upregulation of the
ChREBP target gene Acly was strongly impaired in RetSat-
depleted adipocytes (Supplementary Fig. 8b), suggesting that
RetSat’s control of ChREBP activity is not restricted to
hepatocytes.
Discussion
We discovered a novel function of RetSat in liver metabolism.
RetSat depletion in primary hepatocytes reduced glycolytic flux,
de novo lipogenesis and palmitate desaturation. In HS/HFD-fed
mice, acute depletion of RetSat reduced liver TG content,
improved glucose tolerance, and lowered blood glucose and
serum lipids. Moreover, we found that RetSat expression in liver
correlates positively with body weights in both mice and humans,
consistent with increased hepatic de novo lipogenesis in obese,
insulin-resistant subjects17.
To identify the mechanism by which RetSat has such a pro-
found impact on metabolic pathways, we profiled gene expression
in primary hepatocytes. At first we were surprised to find such a
high number of genes regulated by the sole depletion of this
enzyme. However, this pattern hinted towards a transcriptional
regulator that would function downstream of RetSat. We iden-
tified this transcriptional regulator as ChREBP. We found that
RetSat is required for (1) ChREBP activity, target gene expression,
and its nuclear accumulation upon high glucose exposure in
primary hepatocytes, (2) ChREBP target gene expression in livers
of mice re-fed with NC and (3) ChREBP protein levels and target
gene expression in livers of HS/HFD-fed mice. Moreover, RetSat
expression correlates strongly with that of canonical ChREBP
target genes in human liver samples. Most importantly, acute
depletion of RetSat in livers of HS/HFD-fed mice induced a
phenotype that, in many respects, carries strong resemblance with
that of acute depletion of ChREBP in genetically obese mice,
including a reduction in serum NEFAs and lower blood glucose
levels36. On the basis of these findings, our current working model
places RetSat upstream of ChREBP by catalyzing the generation of
a metabolite that enhances ChREBP’s nuclear translocation, or by
degrading a molecule that mediates cytosolic retention.
RetSat’s regulation of ChREBP activity may be relevant in other
cell types since there is a strong overlap in their tissue expression
pattern. Indeed, we show that RetSat depletion interferes with
glucose sensing and the expression of ChREBP target genes also
in adipocytes. Since we recently reported that activating ChREBP
by high glucose concentrations or expressing a constitutive-active
ChREBP in precursor cells enhances adipocyte differentiation25,
RetSat’ s requirement for in vitro adipocyte differentiation5
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may in fact be due to its ChREBP-activating function.
Reduced RetSat expression in adipose tissue of obese mice and
humans5 is also consistent with its function in de novo lipo-
genesis, since obesity and insulin resistance, in stark contrast to
liver, associate with reduced adipose tissue de novo
lipogenesis17, 24.
Although Srebp1c and Lxrα are interconnected with ChREBP
and partially overlap in controlling glycolytic and lipogenic gene
expression31, 41–43, we have no indication that RetSat directly
affects either of them. However, we would expect that Srebp1c’s
proteolytic activation, functionally more relevant than its mRNA
levels, could be affected in HS/HFD-fed mice depleted of hepatic
RetSat due to low serum insulin levels which are known to affect
its processing44.
By identifying RetSat’s function in liver several questions arise
that should be addressed in future experiments. The most
important is in regard to RetSat’s enzymatic function. Similar to
adipocyte differentiation5, defects due to RetSat depletion were
not overcome by providing the putative enzymatic product 13,14-
dhretinol. If not retinol conversion, by which reaction does RetSat
control ChREBP activity? Molecular cues, including post-
translational modifications, that enhance or prevent nuclear
translocation of ChREBP are complex27, 45–47 and a careful dis-
section may identify RetSat’s involvement. For instance, it has
been hypothesized that RetSat reduces Δ13 of certain poly-
unsaturated fatty acids (PUFAs)48. Since ChREBP activity is
suppressed by PUFAs, but not by MUFAS or saturated fatty
acids35, RetSat may induce ChREBP activity by metabolizing
PUFAs. Notably, not all effects of RetSat depletion can be
explained by working upstream of ChREBP, indicating that
additional mechanisms may play a role. Another puzzling aspect
is that RetSat whole-body knockout mice, even when fed a HFD,
lacked changes in hepatic or serum TG levels11. Whether or not
this is due to compensatory mechanisms that can be invoked in
germline knockout models has to be determined.
Taken together, we found that RetSat coordinates liver meta-
bolism by upstream regulation of ChREBP. When balanced with
metabolically favorable aspects of activated ChREBP, e.g. de novo
lipogenesis in adipose tissue24, and fatty acid desaturation49 and
suppression of SREBP2-mediated detrimental cholesterol over-
load50 in liver, pharmacological inhibition of RetSat and lower
ChREBP activity in liver may have therapeutic potential to treat
hepatic steatosis, dyslipidemia and hyperglycemia.
Methods
Human liver samples. Informed consent was obtained from each patient and the
study protocol conformed to the ethical guidelines of the 1975 Declaration of
Helsinki and was approved by the ethics committee of the Charité -Uni-
versitätsmedizin Berlin (INSIGHT study, German Clinical Trials Register:
DRKS00005450). Twenty-nine patients were eligible for the current study, details
regarding inclusion and exclusion criteria have been published51. To avoid
hypoxia-induced artefacts, perfused liver tissue samples were taken by knife
extraction immediately after starting surgery. Degree of liver steatosis was eval-
uated by means of histopathology according to standard criteria15. Liver samples
were immediately snap-frozen and processed for mRNA and gene expression.
Characteristics of patients are given in Supplementary Table 2. In a subset of higher
yield liver samples (n= 14), lipid profiles were determined based on a published
methodology52. Lipid extracts were methylated by acid- and base-catalyzed pro-
cedures using a combination of 0.5 N methanolic sodium hydroxide (Merck) and
10% (w/w) boron trifluoride-methanol (Supelco, USA, 100 °C for 5 min each).
Subsequently, fatty acid methyl esters (FAME) were purified by thin layer chro-
matography and dissolved in n-hexane for analysis. A system of two gas chro-
matography/flame ionization detector methods was used to analyze the full FA
spectrum (GC-17 V3 Shimadzu, DB-225MS Agilent and GC-2010, Shimadzu, CP-
select, Varion). FA data are presented as percentage of the total area of all FA peaks
(% of total FAME).
Animal studies. Animal procedures were in accordance with institutional guide-
lines and approved by the corresponding authorities (approval at the University of
Pennsylvania by the Institutional Animal Care and Use Committee, and at the
Charité by the Landesamt für Gesundheit und Soziales Berlin). Male C57BL/6 J
mice (provided by the Jackson Laboratory or the Research Institute for Experi-
mental Medicine of the Charité) aged 6–8 weeks were used for all experiments if
not stated otherwise. Mice were fed either normal chow (NC, ssniff R/M-H) or a
60 kcal% high-fat/high-sucrose diet (HS/HFD, D12492, Research Diets). Obese and
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insulin-resistant mice were obtained feeding 6-week-old mice HS/HFD for at least
8 weeks. For fasting experiments, cages were replaced and food withheld for 24 h.
Re-feeding experiments were carried out by providing chow diet for 4 h after the
24 h fasting period. For comparing hepatic RetSat expression in lean or diet-
induced obese mice, a previously described cohort was used5.
Adenovirus generation and tail-vein injection into mice. Adenoviral vectors
expressing shRNA against β-Galactosidase (βGal) or RetSat were cloned using the
BLOCK-iT U6 RNAi Entry Vector Kit and Adenoviral RNAi Expression System
according to the manufacturer’s instructions (ThermoFisher). Adenoviruses
expressing GFP or a GFP- murine ChREBP fusion protein are described else-
where25. Viruses were amplified in HEK293 cells (Clontech) and purified by
standard CsCl gradient centrifugation and dialyzed against 0.9% saline. Titers were
determined by the Adeno-X Rapid Titer Kit (Clontech). For liver-selective RetSat
depletion, ~10E10 infectious units of shβGal-or shRetSat-expressing adenoviruses
were injected via the tail vein into lean or obese, insulin-resistant mice.
Mouse characterization. 24 h food intake was determined three days after virus
injection. Five days after injection, mice were fed ad libitum or starved for 24 h,
blood glucose determined (Contour, Bayer) and sacrificed. Serum was obtained by
cardiac puncture and organs collected for protein and mRNA analyses. Liver TG
were determined after hydrolyzing ~50 mg of liver tissue for 5 h at 60 °C with 1:1
volume ethanol/30% KOH. After adding equal volumes of 1 M MgCl2 and 10 min
incubation on ice, samples were centrifuged and TG-derived glycerol content in the
liquid phase determined (Diasys). Serum TG (Diasys), NEFAs (Wako diagnostics)
and insulin (Rat Insulin ELISA, CrystalChem) were measured by the indicated kits.
For histology, liver pieces were fixed overnight in 4% paraformaldehyde and
embedded in OCT for cryosectioning and subsequent Oil Red-O staining. Glucose
tolerance was determined by intraperitoneal (ip.) injection of 0.5 g/kg glucose after
a 16 h fasting period and repeated blood glucose measurements. Insulin tolerance
was assessed by ip. injection of 0.75 U/kg insulin (Insuman rapid, Sanofi) after a 6 h
fasting period and blood glucose measurements after the indicated times.
Measurement of hepatic de novo lipogenesis. Mice were fed ad libitum and ip.
injected with deuterated water (Sigma) (20 μl per gram body weight). Mice were killed
6 h later and liver tissue and whole blood collected. Palmitate content was analyzed
using gas chromatography-mass spectrometry. We determined the percentage con-
tribution of newly made fatty acid using the equation: percentage of newly made fatty
acid= (total 2H-labeled fatty acid/(2H-labeled body water × n)) × 100, where n is the
number of exchangeable hydrogens, assumed to equal 22 for palmitate. We deter-
mined the absolute amount of newly synthesized fatty acids by multiplying the
percentage of newly made fatty acids by the concentration of the total fatty acids53.
Primary hepatocyte isolation and cell culture. Isolation of hepatocytes was
performed as previously described54 with slight modifications. Mice were anes-
thetized by ip. injection of ketamine-xylazine and livers perfused via the inferior
vena cava with 25 ml of pre-warmed perfusion buffer (Earle’s Balanced Salt
Solution w/o CaCl2/MgCl2 (ThermoFisher)) followed by perfusion with 30 ml of
pre-warmed digestion buffer (Hank’s Salt Solution w/o Phenol red (ThermoFisher),
supplemented with 5000 U collagenase (Worthington)). The excised liver was
minced, the cell suspension filtered through a 250 micron mesh filter, and hepa-
tocytes collected by a Percoll gradient centrifugation (GE Healthcare). Cell viability
was assessed by Trypan Blue staining and hepatocytes seeded on collagen-coated
12-well plates (250,000 cells per well) in Dulbecco’s modified Eagle’s medium
(DMEM) w/o pyruvate containing 25 mM glucose, 10% fetal bovine serum (FBS)
(Invitrogen) and 1% penicillin/streptomycin (GIBCO). 3T3-L1 cells (ATCC) were
grown to confluence in DMEM w/o pyruvate containing 25 mM glucose, 10% FBS,
and penicillin/streptomycin (ThermoFisher). Adipocyte conversion of 3T3-L1 cells
was induced by supplementing 10 µg/ml insulin, 2 µM dexamethasone and 500 µM
isobutylmethylxanthine for 2 days and for another 2 days by 10 µg/ml insulin
only55. Cells were used for experiments when at least 90% were differentiated to
adipocytes. HEK293 cells were grown in DMEM containing 10% FBS and 1%
penicillin/streptomycin. Glucose concentrations for sensing experiments were used
as indicated. Cells were not tested for mycoplasma contamination.
siRNA-mediated silencing in hepatocytes and 3T3-L1 adipocytes. After the
attachment of hepatocytes to the cell culture plate, media was replaced by 500 µl of
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DMEM without supplements, and cells transfected with 1 nmol of siRNA (Euro-
gentec) and 4 µl of Lipofectamine 2000 (Invitrogen) per 12-well overnight. The
next morning, media was replaced by DMEM containing 10% FBS and 1% peni-
cillin/streptomycin. siRNA-mediated silencing in 3T3-L1 adipocytes was per-
formed by electroporation (Nucleofector solution V, Lonza) with 3 nmol of siRNA
(Eurogentec, Supplementary Table 3).
GC-MS based metabolomics and de novo lipogenesis in hepatocytes. Hepa-
tocytes were harvested using cooled (−20 °C) 50% MeOH/H20. To analyze incor-
poration of 13C carbon in central glycolytic intermediates, cells were incubated for
5 min with 13C6 glucose (Sigma) and label incorporation was analyzed as pre-
viously described56. Extracts were transferred to falcon tubes and chloroform was
added to achieve mixture of methanol-chloroform-water (MCW) (5:2:1/v:v:v)
(Methanol LC-MS-grade, Chloroform Reagent Plus 99,8% Sigma-Aldrich); cin-
namic acid as internal standard (Sigma-Aldrich) was added (2 mg/ml). Supernatant
was collected and shaken at 750 r.p.m. and 4 °C for 60 min followed by cen-
trifugation for 10 min at 5000 g to separate the polar (top), lipid (bottom) and
interface (tissue debris) layers. Polar and lipid phases were dried under vacuum for
12 h. Polar and lipid extracts were processed and analyzed using gas
chromatography-mass spectrometry (GC-MS)57. Metabolite analyses were per-
formed by a Pegasus III mass-spectrometer (LECO, St. Joseph, USA) equipped with
an Agilent 6890 N gas chromatograph and a VF-5ms column with 30 m length and
250 µm inner diameter (Agilent, Santa Clara, USA). 1 µl of sample was injected into
a baffled liner (Gerstel, München, Germany) with a 1:5 split-ratio under a helium-
flow of 1.2 ml/min. The oven was heated from 70 to 350 °C with 5 °C/min to 120 °C
and 7 °C/min to 350 °C followed by 2 min hold time. Scan rates of 20 Hz and mass
ranges of 70–600 Da were used. The GC-MS chromatograms were initially
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processed with the ChromaTOF software (LECO). The Golm metabolome database
(GMD) was used to identify substances in chromatograms achieved from polar and
lipid phases with respect to spectra-similarity and retention index. Data matrices
for relative quantification were extracted from the mass spectra using MetMax
software57 and metabolite data were normalized to the internal standard measured
in the corresponding sample. Lipogenesis was determined by incubating primary
hepatocytes with 0.25 µCi/ml [1-14C]-acetic acid and 25 mM glucose with or
without 100 nM insulin for 2 h. Cells were then washed 3× with PBS and harvested
in 1:1 volume ethanol/30% KOH. After saponification at 70 °C for 2 h and acid-
ification with 5M sulfuric acid, total lipids were extracted by hexane and incor-
porated 14C radioactivity measured by scintillation.
Confocal microscopy. Cells were fixed with 4% paraformaldehyde on ice for 20
min, washed with PBS and permeabilized with 0.5% Triton X-100 at room tem-
perature (RT) for 15 min. To block non-specific staining, cells were washed and
incubated for 1 h at RT in PBS containing 3% BSA and 0.02% Tween and
immunolabeled overnight at 4 °C with primary antibodies: RetSat5 (diluted 1:300 in
3% BSA with 0.02% Tween20), ChREBP (NB400-135, Novus Biologicals, lot M1,
diluted 1:300 in 3% BSA with 0.02% Tween20). Cells were washed and incubated
with fluorochrome-conjugated secondary antibody (Alexa Fluor® 555 (Life Tech-
nologies, diluted 1:600 in 3% BSA) for 1 h at RT. Cells were washed and nuclei were
stained with DAPI (Life Technologies) and mounted in Mowiol. Cells were imaged
using a confocal microscope (Leica DM 2500). Background subtraction was per-
formed and intensities were quantified by ImageJ software.
Luciferase reporter assays. Following transfection of primary hepatocytes with
control or RetSat siRNA overnight, cells were transfected with a reporter that
contained two copies of the ACC1 carbohydrate response element (ChoRE) in its
promoter driving firefly luciferase expression33 using lipofectamine in the presence
of 5.5 mM glucose and 100 nM insulin for 4 h. Culture medium was changed to
either 5.5 or 27.5 mM glucose and 100 nM insulin and cells harvested 16 h later.
ChoRE-firefly luciferase reporter activity was normalized to co-expressed renilla
luciferase (Dual Luciferase, Promega).
Immunoblotting. Whole-tissue or whole-cell proteins were isolated and homo-
genized by standard methods and separated by sodium dodecyl
suphate–polyacrylamide gel electrophoresis. Protein concentrations were deter-
mined by the BCA method (Thermo Scientific). After incubation with antibodies
for RetSat5 (diluted 1:1000 in 4% skimmed milk), ChREBP (NB400-135, lot J1,M1
or M6 (Novus Biologicals, diluted 1:1000 in 0.05% BSA)25 (both antibodies were
validated in the referenced studies), Ran (#610340, BD Biosciences, diluted 1:1000
in 4% skimmed milk), Anti-flag (A8592, Sigma, diluted 1:1000 in 4% skimmed
milk), β-Actin (sc-47778, Santa Cruz, diluted 1:1000 in 4% skimmed milk),
phospho Akt (S473, #4060, Cell Signaling, diluted 1:1000 in 4% BSA), and total Akt
(#9272, Cell Signaling, diluted 1:1000 in 4% BSA), secondary horseradish-
conjugated antibodies (goat anti-rabbit (#31460, Pierce) and goat anti-mouse
(#31440, Pierce), diluted 1:1000-1:5000 in 4% skimmed milk) were added as
appropriate and a chemiluminescent substrate kit (Thermo) used for detection.
Isolation and quantification of mRNA expression. RNA was purified using spin
column kits (Macherey-Nagel, Germany). cDNA was generated using MMLV-RT
(Promega) or the High Capacity cDNA Reverse Transcription Kit (Applied Bio-
systems). qPCRs were performed using Sybrgreen PCR Mastermix (Roche) and
evaluated according to the standard curve method. All mRNA expression data were
normalized to murine 36B4 or human HPRT. Primer sequences are listed in
Supplementary Table 3. Gene expression profiling was performed using Affymetrix
Mouse Gene 1.0 ST Array arrays by hybridizing three independent transfections of
control or RetSat siRNA-treated primary hepatocytes as described previously5 by
the University of Pennsylvania Microarray Core Facility. Gene Ontology analysis of
regulated genes was performed using DAVID58, 59. Row-normalized heatmaps
were generated by the Heatmap Builder.
Statistical analyses. Statistical tests are described in the respective figure legends.
Sample size estimate for mouse studies was based on power analyses using the
analysis platform at the University of Muenster (https://campus.uni-muenster.de/
fileadmin/einrichtung/imib/lehre/skripte/biomathe/bio/falla.html). With the
observed group differences and the expected variation of measured in vivo para-
meters, n= 5 will provide more than 90% power at the type I error rate of 0.05.
Mouse experiments were not randomized or conducted blind to conditions, no
exclusion criteria were defined. After testing for normal distribution, statistical
analysis was performed using one-way analysis of variance (ANOVA) followed by
Bonferroni post test when more than two groups were compared, two-way
ANOVA followed by Bonferroni post test when two conditions were investigated
and a two tailed Students’s t test when only two groups of data were concerned, and
P< 0.05 was deemed significant. Correlation analyses regarding human data were
performed using the Pearson or Spearman rank correlation coefficient. Statistical
analyses were calculated by GraphPad Prism (GraphPad Software).
Data availability. Affymetric expression profiling data of primary hepatocytes
depleted of RetSat that support the findings of this study have been deposited in the
Gene Expression Omnibus (GEO) repository60 with the accession code
GSE100211.
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